[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100611855":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":39,"responsibleParty":56,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":25,"enrollmentInfo":68,"targetDuration":25,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":82,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Queen Mary University of London","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Continue pre prescribed rivaroxaban or apixaban or warfarin","EXPERIMENTAL","If randomised to this arm, participants will continue on their rivaroxaban or apixaban or warfarin for the study related time period.",[13],"Drug: Continue rivaroxaban or apixaban or warfarin",{"label":15,"type":10,"description":16,"interventionNames":17},"Discontinue pre prescribed rivaroxaban or apixaban or warfarin","If randomised to this arm, patients (who have already been on OAC for a period of 3 months) will discontinue their rivaroxaban or apixaban or warfarin.",[18],"Drug: Discontinue rivaroxaban or apixaban or warfarin",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Continue rivaroxaban or apixaban or warfarin","The study is asessing the impact of discontinuation of oral anticoagulation in patients with LV thrombus diagnosis.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Discontinue rivaroxaban or apixaban or warfarin","discontinue rivaroxaban or apixaban or warfarin",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Dr Dan Jones","CONTACT","02037658707","dan.jones8@nhs.net",{"name":37,"role":33,"phone":34,"phoneExt":25,"email":38},"Mervyn Andiapen","mervyn.andiapen@nhs.net",[40],{"facility":41,"status":25,"city":42,"state":25,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"St Bartholomews Hospital","London","EC1A4BE","United Kingdom","UK",{"type":47,"coordinates":48},"Point",[49,50],-0.12574,51.50853,{"lat":50,"lon":49},[53,54],{"name":37,"role":33,"phone":34,"phoneExt":25,"email":38},{"name":32,"role":55,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":57,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100611855","phase-2-lvt-duration-pilot-study-of-anticoagulation-duration-for-left-ventricular-thrombus-100611855",false,"NCT07246005","LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus","LVT Duration","Inclusion Criteria:\n\n* Diagnosis of LV thrombus less than 12 months ago\n* On Apixaban at the time of randomisation\n* Completed at least 3 months of anticoagulation treatment for LV thrombus\n* Persistent laminar\u002F mural thrombus or persistent LV dysfunction\n\nExclusion Criteria:\n\n* Any clinical condition requiring long term anticoagulation treatment as per investigator's judgement.\n* SSE since LV thrombus diagnosis\n* Contraindication to continuing anticoagulation therapy\n* Non-ischaemic Cardiomyopathy\n* Age less than 18 years\n* Unable to consent","ALL","18 Years",{"count":69,"type":70},120,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are:\n\n* To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement.\n* To identify the optimal length of anticoagulation in the treatment of LV Thrombus\n\nAfter randomisation participants will:\n\n* Continue their prescribed oral anticoagulant for the remainder of the trial\n* Discontinue their prescribed oral anticoagulant for the remainder of the trial",[76],"Left Ventricular Thrombus",[78,76,79,80,81],"LVT","Thrombus","Thrombi","anticoagulant","NOT_YET_RECRUITING","2026-02-26",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":70},"2026-12-01",{"date":90,"type":70},"2027-12-01",{"name":5,"class":6},1]